Iovance Biotherapeutics, Inc. announced that Wendy Dixon, Ph.D. who has been a member of Board of Directors since 2022, will not stand for re-election at the Annual Meeting, to be held on June 6, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.45 USD | +3.55% |
|
+5.62% | +3.94% |
06-20 | JMP Securities Adjusts Price Target on Iovance Biotherapeutics to $23 From $25, Maintains Market Outperform Rating | MT |
06-11 | Iovance Biotherapeutics, Inc. Elects Frederick G. Vogt as Director | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.94% | 2.36B | |
-44.08% | 7.63B | |
+8.98% | 3.61B | |
-24.94% | 1.86B | |
-17.38% | 1.74B | |
+4.89% | 913M | |
+21.75% | 763M | |
-11.57% | 678M | |
-30.82% | 500M | |
+4.37% | 290M |
- Stock Market
- Equities
- IOVA Stock
- News Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics, Inc. Announces Wendy Dixon, Member of Board of Directors, Will Not Stand for Re-Election